EFNB1 and hepatocellular carcinoma: HCC patients with high EFNA3 and EFNA4 expression were found to be more responsive to cisplatin, doxorubicin, gemcitabine, and mitomycin C, while high EFNB1 expression was associated with better responses to doxorubicin, gemcitabine, and mitomycin C, but poorer responses to cisplatin and sorafenib [95].